Peripheral and tissue-resident gamm/delta T cells in HIV latency
HIV潜伏期的外周和组织驻留γ/δ T细胞
基本信息
- 批准号:9204152
- 负责人:
- 金额:$ 47.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-05 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntiviral TherapyBiologicalCD4 AntigensCD4 Lymphocyte CountCell physiologyCellsChronic PhaseComplementDNADevelopmentEarly treatmentGut associated lymphoid tissueHIVHIV InfectionsHIV-1Histone Deacetylase InhibitorHumanImmune responseImmune systemIn VitroInfectionInvestigationKnowledgeLicensingLifeLiverLymphocyteLymphoid TissueMeasurementMemoryNormal RangePatientsPeripheralPharmaceutical PreparationsPopulationRestRoleSignal TransductionSiteStimulusSurfaceT-Cell DepletionT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTherapeuticTimeTissuesViralViral reservoirVirusadaptive immunityantiretroviral therapybone lossgastrointestinalin vivointraepitheliallatent infectionmemory CD4 T lymphocytenovelperipheral blood
项目摘要
Project Summary
Identification and description of all cellular reservoirs of persistent HIV infection is of crucial importance
to HIV eradication efforts. There is increasing evidence of the existence of additional latent reservoirs in the
peripheral blood, and also within the tissue where a substantial fraction of the total lymphocytes of the body are
located. We have discovered that a subclass of γδ T cells that express the Vδ2 TCR chain, harbor latent but
replication-competent HIV. Furthermore, we have described a mechanism to explain Vδ2 cell infection,
showing that although these cells generally express extremely low levels of the CD4 receptor, they can
upregulate the CD4 receptor following stimuli in vitro. We have confirmed this finding by the discovery that
acutely HIV-infected patients studied less than three weeks after infection, are found to have substantial
expression of the CD4 receptor on Vδ2 cells.
We propose to validate and clarify the importance of this new latent HIV reservoir within γδ T cells by i)
extending our studies to include the complementary Vδ1 TCR γδ T cell population, as we find significant levels
of HIV DNA within this second γδ T cell population, ii) studying infection and latency within γδ T cells in the gut
associated lymphoid tissue (GALT), lymphoid tissues (LT) and liver, given the predominance of γδ T cells
within these tissues, iii) analyze the stability and durability of latency within the γδ T cell reservoir, and iv)
explore therapeutic approaches to disrupt latency within γδ T cells. Our investigations will contribute critically to
the effort to define and eradicate HIV infection within all persistent, latently infected cells.
项目概要
识别和描述持续性艾滋病毒感染的所有细胞储存库至关重要
消灭艾滋病毒的努力。越来越多的证据表明,该地区还存在着额外的潜在储库。
外周血,以及体内大部分淋巴细胞所在的组织内
位于。我们发现表达 Vδ2 TCR 链的 γδ T 细胞亚类具有潜在但
有复制能力的HIV。此外,我们描述了一种解释 Vδ2 细胞感染的机制,
表明虽然这些细胞通常表达极低水平的 CD4 受体,但它们可以
体外刺激后上调 CD4 受体。我们通过以下发现证实了这一发现:
研究人员在感染后不到三周的时间内对急性艾滋病毒感染者进行了研究,结果发现,
Vδ2 细胞上 CD4 受体的表达。
我们建议通过 i) 验证和澄清 γδ T 细胞内这种新的潜在 HIV 储存库的重要性
将我们的研究扩展到包括互补的 Vδ1 TCR γδ T 细胞群,因为我们发现显着水平
第二个 γδ T 细胞群中 HIV DNA 的分析,ii) 研究肠道 γδ T 细胞内的感染和潜伏期
鉴于 γδ T 细胞占主导地位,相关淋巴组织 (GALT)、淋巴组织 (LT) 和肝脏
在这些组织内,iii) 分析 γδ T 细胞库内潜伏期的稳定性和持久性,以及 iv)
探索破坏 γδ T 细胞内潜伏期的治疗方法。我们的调查将至关重要
努力定义和根除所有持久性、潜伏感染细胞内的艾滋病毒感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Soriano-Sarabia其他文献
Natalia Soriano-Sarabia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Soriano-Sarabia', 18)}}的其他基金
Allogeneic cytotoxic gammadelta T cells for HIV cure immunotherapy
用于 HIV 治愈免疫治疗的同种异体细胞毒性 γδ T 细胞
- 批准号:
10383737 - 财政年份:2021
- 资助金额:
$ 47.33万 - 项目类别:
Allogeneic cytotoxic gammadelta T cells for HIV cure immunotherapy
用于 HIV 治愈免疫治疗的同种异体细胞毒性 γδ T 细胞
- 批准号:
10256995 - 财政年份:2021
- 资助金额:
$ 47.33万 - 项目类别:
Peripheral and tissue-resident gamm/delta T cells in HIV latency
HIV潜伏期的外周和组织驻留γ/δ T细胞
- 批准号:
9310444 - 财政年份:2016
- 资助金额:
$ 47.33万 - 项目类别:
Peripheral and tissue-resident gamm/delta T cells in HIV latency
HIV潜伏期的外周和组织驻留γ/δ T细胞
- 批准号:
10075004 - 财政年份:2016
- 资助金额:
$ 47.33万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 47.33万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 47.33万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 47.33万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 47.33万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 47.33万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 47.33万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 47.33万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 47.33万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 47.33万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
- 批准号:
449805 - 财政年份:2020
- 资助金额:
$ 47.33万 - 项目类别:
Studentship Programs














{{item.name}}会员




